Medtronic and Merit Medical Systems enter into agreement to offer new, FDA-cleared ViaVerteâ"¢ system, a basivertebral nerve ablation treatment for chronic vertebrogenic lower-back pain Accessibility StatementSkip Navigation Exclusive agreement expands Medtronic's comprehensive pain interventions portfolio, increases treatment options for patients living with chronic pain GALWAY, Ireland, March 24, 2026 /PRNewswire/ -- Medtronic plc, a global leader in healthcare technology, today announced that it has ente ...

Key Takeaways Merit Medical unveils Resilience TTS stent to treat esophageal fistulas and malignant strictures.MMSI's device targets clinical gaps with an anti-migration design and a single-handed delivery system.Merit Medical expands endoscopy portfolio with multiple size options to improve patient care flexibility.Merit Medical Systems (MMSI) announced the U.S. commercial launch of its Resilience Through-the-Scope (TTS) Esophageal Stent. The Resilience stent expands the company’s endoscopy portfolio, addi ...

For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both.The popular research service can help you become a smarter, more self-assured investor, giving you access to daily updates of the Zacks Rank and Zacks Industry Rank, the Zacks #1 Rank List, Equity Research reports, and Premium stock screens.Zacks Premium also includes the Zacks Style Scores. What are the Zacks Style Scores? The Zacks St ...

Core Insights - Merit Medical Systems, Inc. (MMSI) reported a strong performance in Q4 2025, with adjusted earnings per share (EPS) of $1.04, reflecting a 12% increase year-over-year and surpassing the Zacks Consensus Estimate by 8.3% [1] - The company achieved total revenues of $393.9 million in the fourth quarter, an 11% increase year-over-year, also exceeding the Zacks Consensus Estimate by 0.8% [2] Revenue Details - Q4 revenues were $393.9 million, up 11% year-over-year, with constant exchange rate (CER) revenues increasing by 10% and organic revenues rising by 6.8% [2] - Full-year revenues reached $1.52 billion, marking a 12% increase on a reported basis, with 11% growth at CER and 7% growth in CER organic revenues [2] Geographic Performance - U.S. sales were $238.2 million, up 11.6% year-over-year, while international sales reached $155.7 million, a 9.9% increase [3] - Asia-Pacific revenues were $62.7 million, up 3.1%, and revenues from Europe, the Middle East, and Africa totaled $77.4 million, up 18.8% [4] Segment Performance - The Cardiovascular segment generated $373.9 million in Q4, an 11% increase year-over-year, with notable growth in Peripheral Intervention (PI) and Cardiac Intervention (CI) product lines [6][7] - PI revenues were $154.9 million, up 15%, while CI revenues reached $117.2 million, a 23% increase [7] Margin Analysis - Gross profit for Q4 increased by 12.9% to $195.3 million, with adjusted gross margin expanding by 100 basis points to 54.5% [10] - Adjusted operating profit rose 18.7% to $82.7 million, with an adjusted operating margin of 21% [11] Financial Position - At the end of Q4 2025, cash and cash equivalents stood at $446.4 million, up from $392.5 million in Q3, while total long-term debt was $734 million [12] - Cumulative net cash from operating activities reached $297.4 million, compared to $220.8 million a year ago [12] Guidance - For 2026, MMSI projects revenues between $1.61 billion and $1.63 billion, reflecting a 6-8% increase year-over-year, with adjusted EPS expected to be in the range of $4.01-$4.15 [13] Overall Assessment - The company demonstrated impressive year-over-year growth in both revenue and earnings, with strong performance across its segments and product categories, except for OEM [14] - The robust revenue growth in the U.S., EMEA, and APAC regions, along with margin expansion, positions the company favorably for future growth [15]

Core Insights - Merit Medical reported revenue of $393.94 million for the quarter ended December 2025, reflecting a year-over-year increase of 10.9% and exceeding the Zacks Consensus Estimate of $390.83 million by 0.8% [1] - The company's EPS for the quarter was $1.04, up from $0.93 in the same quarter last year, and surpassed the consensus EPS estimate of $0.96 by 8.9% [1] Financial Performance - The stock has returned -1.1% over the past month, slightly underperforming the Zacks S&P 500 composite's -1% change [3] - Merit Medical holds a Zacks Rank 2 (Buy), indicating potential for outperformance in the near term [3] Geographic Sales Breakdown - United States: $238.22 million, exceeding the average estimate of $234.37 million, with a year-over-year change of +11.6% [4] - APAC: $62.72 million, above the estimated $60.69 million, representing a +3.1% change year over year [4] - International: $155.71 million, surpassing the average estimate of $152.71 million, with a +10% year-over-year change [4] - Rest of World: $15.62 million, slightly above the estimate of $15.31 million, with a year-over-year change of -0.2% [4] - EMEA: $77.37 million, exceeding the average estimate of $76.71 million, reflecting an +18.8% year-over-year change [4] Revenue by Segment - Cardiovascular - Peripheral Intervention: $154.93 million, above the average estimate of $148.66 million, with a +10.4% year-over-year change [4] - Cardiovascular - Cardiac Intervention: $117.24 million, exceeding the estimated $111.56 million, representing a +22.5% change year over year [4] - Endoscopy: $20.06 million, slightly above the average estimate of $19.97 million, with a +14.9% year-over-year change [4] - Cardiovascular - OEM: $48.09 million, below the average estimate of $55.76 million, reflecting a -4.7% year-over-year change [4] - Total Cardiovascular revenue: $373.88 million, exceeding the average estimate of $368.79 million, with a +10.7% year-over-year change [4] - Cardiovascular - Custom Procedural Solutions: $53.62 million, above the estimated $52.82 million, representing a +4.7% change year over year [4]

分组1 - Merit Medical reported quarterly earnings of $1.04 per share, exceeding the Zacks Consensus Estimate of $0.96 per share, and showing an increase from $0.93 per share a year ago, resulting in an earnings surprise of +8.90% [1] - The company achieved revenues of $393.94 million for the quarter ended December 2025, surpassing the Zacks Consensus Estimate by 0.80%, and up from $355.16 million year-over-year [2] - Merit Medical has consistently surpassed consensus EPS estimates over the last four quarters, achieving this four times [2] 分组2 - The stock has underperformed the market, losing about 7.4% since the beginning of the year, compared to a decline of 0.1% for the S&P 500 [3] - The current consensus EPS estimate for the upcoming quarter is $0.89 on revenues of $379.6 million, and for the current fiscal year, it is $4.05 on revenues of $1.6 billion [7] - The Medical - Dental Supplies industry, to which Merit Medical belongs, is currently ranked in the top 38% of over 250 Zacks industries, indicating a favorable outlook for the sector [8]

Financial Data and Key Metrics Changes - The company reported total revenue of $393.9 million for Q4 2025, representing an 11% year-over-year increase on a GAAP basis and a 10% increase on a constant currency basis [6][7] - Non-GAAP operating margin increased by 138 basis points year-over-year to 21% [7][18] - Non-GAAP EPS grew by 12% year-over-year, exceeding expectations [8] - Free cash flow for Q4 was $74 million, up 13% year-over-year, marking a quarterly record for the company [8][19] - For the full year 2025, the company achieved constant currency revenue growth of 11% and generated nearly $216 million in free cash flow, up 16% year-over-year [19][20] Business Line Data and Key Metrics Changes - Q4 total revenue growth was driven by a 9% increase in the cardiovascular segment and a 15% increase in the endoscopy segment [10] - Cardiac Intervention product sales increased by 21%, with organic growth driven by strong sales in EP, CRM, angiography, and access products [11][12] - Peripheral Intervention products sales increased by 13%, primarily driven by strong sales in Radar Localization and delivery systems [13] - Sales of custom procedural solutions products increased by 4%, while OEM products sales decreased by 15% [14][15] Market Data and Key Metrics Changes - U.S. sales increased by 12% year-over-year, while international sales increased by 6% [16] - U.S. organic constant currency sales growth was 8%, and international organic constant currency sales growth was 4% [16] Company Strategy and Development Direction - The company aims to drive strong execution globally and successfully complete its Continued Growth Initiatives program, targeting a 5%-7% organic constant currency revenue CAGR for the three-year period ending December 31, 2026 [9][37] - The divestiture of the DualCap product line is expected to create additional manufacturing capacity and free up resources for higher-margin products [24][38] - The company is focused on both internal product innovation and strategic M&A to enhance its competitive position [36][59] Management's Comments on Operating Environment and Future Outlook - Management acknowledged the challenges posed by the dynamic global macro environment but expressed confidence in the company's strong execution and commitment to financial targets [9][19] - The company expects solid constant currency growth and non-GAAP operating margin expansion in 2026, despite potential headwinds from tariffs and trade policies [22][25] Other Important Information - The company introduced financial guidance for 2026, projecting total GAAP net revenue growth of 6%-8% year-over-year and free cash flow of at least $200 million [22][27] - The expected impact of tariffs on non-GAAP EPS for 2026 is approximately $0.19 per share [25][26] Q&A Session Summary Question: What are the additional gross margin drivers for the company? - Management emphasized the importance of mix, pricing, cost discipline, and SKU rationalization to drive gross margin improvements [42][44] Question: How is the WRAPSODY product performing in the outpatient setting? - Management acknowledged that initial revenue expectations for WRAPSODY were missed but expressed confidence in achieving the $7 million revenue target for 2026 [46][48] Question: What factors are influencing the guidance for free cash flow in 2026? - Management indicated that the guidance reflects a conservative approach due to timing-based factors and ongoing capital expenditures [52][54] Question: What areas is the company looking at for potential M&A? - The company is focusing on both foundational and therapeutic products, seeking strategic opportunities that align with its growth drivers [56][59] Question: What is the outlook for the OEM business? - Management noted that the OEM business is expected to normalize to mid-to-high single-digit growth, despite recent inventory destocking [62][63]

Merit Medical Systems (NasdaqGS:MMSI) Q4 2025 Earnings call February 24, 2026 04:30 PM ET Company ParticipantsAidan Lahey - Equity Research AssociateBrian G. Lloyd - Chief Legal Officer and Corporate SecretaryMartha Aronson - President and CEORaul Parra - CFO and TreasurerConference Call ParticipantsDavid Rescott - Director and Senior Research AnalystJason Bednar - Managing Director and Senior Research AnalystJayson Bedford - Managing Director and Senior AnalystJim Sidoti - Senior Equity AnalystJohn Young - ...

Merit Medical Systems (NasdaqGS:MMSI) Q4 2025 Earnings call February 24, 2026 04:30 PM ET Speaker10Welcome to the Merit Medical Systems fourth quarter 2025 earnings conference call. At this time, all participants have been placed in listen-only mode. Please note that this conference call is being recorded and that the recording will be available on the company's website for replay shortly. I would now like to turn the call over to Martha Aaronson, Merit Medical Systems President and Chief Executive Officer. ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended December 31, 2025 MERIT MEDICAL SYSTEMS, INC. (Exact name of registrant as specified in its charter) Utah 87-0447695 (IRS Employer Identification No.) (State or other jurisdiction of incorporation or organization) or ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act ...